Brought to you by 
Evotec Neurosciences gets rights to Roche's CNS compounds; terminated
24 May 2011
Executive Summary
Evotec Neurosciences GMBH (CNS diseases) has exclusively licensed worldwide development and marketing rights to Roche's portfolio of NMDA receptor NR2B subtype selective antagonists to treat Alzheimer's and Parkinson's diseases and neuropathic pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Evotec Neurosciences gets rights to Roche's CNS compounds; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice